Incyte Q3 2026: A $1.23B Charge Masks Broad Revenue Strength
As seen on the 24/7 Wall St. homepage on October 29, 2026.
Opzelura sales grew 36% as Jakafi's patent clock keeps ticking, and that is the number that decides what this company looks like after 2029. The quarter's loss is entirely the Vega Therapeutics IPR&D charge, and management still raised full-year sales guidance.
Continue ReadingShow less
Incyte's Q3 2026 loss of $3.60 per share, beating expectations, is almost entirely explained by a single item: a $1.23 billion in-process research and development charge tied to the July acquisition of Vega Therapeutics. Strip that out and the underlying business posted revenue of $1.56 billion, ahead of expectations.
Growth ran across the commercial portfolio in the quarter. Opzelura grew 36%, and Zynyz and Niktimvo both expanded as well. Even Jakafi, the legacy myelofibrosis franchise whose U.S. patent protection runs out around 2029, posted growth driven by higher paid demand across all indications.
The patent clock on Jakafi is the defining tension for Incyte's long-term thesis, and this quarter management offered its clearest answer yet. CEO Bill Meury pointed to a pipeline led by a CALR-targeted monoclonal antibody for myeloproliferative neoplasms, a KRAS G12D inhibitor for pancreatic and colorectal cancers, the Vega-derived latarcibart program for von Willebrand disease, and a TGFβR2 times PD-1 bispecific for colorectal cancer, arguing those assets together provide multiple paths to growth beyond 2029.
Sponsored
Incyte raised full-year 2026 total net sales guidance to a range of $5.21 billion to $5.30 billion and lifted its Opzelura outlook. Near-term catalysts include Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa expected in Q4 2026, plus U.S. approval decisions for povorcitinib in HS and Monjuvi in newly diagnosed DLBCL as early as Q1 2027.
The Vega acquisition cost $1.25 billion upfront plus additional sales milestones, and its lead asset, latarcibart, is in a Phase 3 study with topline data not expected until early 2029. That means investors are essentially being asked to look past a multi-billion-dollar spending cycle and a Jakafi patent cliff at the same time, with the updated guidance and Opzelura's momentum as the near-term evidence that management's confidence is grounded in the numbers.
Mentioned: INCY